Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN)

Diabetes Mellitus, Type 1 Clinical Trial

— DAWN  

Official title:

A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of TOL-3021 in Patients With New Onset Type 1 Diabetes Mellitus

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03794973
• Other study ID #: TOL-3021-220
• Status: Withdrawn
• Phase: Phase 2
• Start date: December 14, 2019
• Est. completion date: December 14, 2023

Study information

• Verified date: December 2020
• Source: Tolerion, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is a prospective, randomized, double-blind, placebo-controlled, multi-center trial in subjects with new onset T1D.

Description:

The study will include 210 male or female subjects aged 12 to 35 years diagnosed with T1D, as defined by the American Diabetes Association (ADA) criteria and meeting enrollment criteria as follows. Initial enrollment will be restricted to subjects aged 18 and older until an analysis of data from subjects with 3 months' exposure to drug confirms safety. Upon completion of this assessment, enrollment will be open without further restrictions for subjects aged 12-35.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 14, 2023
• Est. primary completion date: December 14, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 35 Years

Eligibility

Inclusion Criteria:

1. Diagnosis of Type 1 Diabetes Mellitus based on American Diabetes Association (ADA) criteria and =100 days since diagnosis, defined as the first day of insulin administration (subjects must be able to be randomized within the 100-day period from diagnosis) .

2. Adequate glycemic control for >14 days, defined as 3 consecutive fasting glucose levels by self-administered blood glucose (SMBG) or lab testing at <130 mg/dL.

3. Age at randomization of 12.0 - <18.0 years (adolescent), 18.0 - <36.0 years of age (adult) ..

4. HbA1c <10.0% based on point-of-care or local lab measurement.

• Measurement can be repeated every 5-7 days if >10.0%.

5. Presence of antibodies to at least one of the following antigens: GAD-65, IA-2, ZnT8; or insulin, if obtained within 10 days of the onset of exogenous insulin therapy.

6. Willingness to wear a continuous glucose monitoring (CGM) device for specified periods of time.

7. Written informed consent, including authorization to release health information and assent for adolescent subjects.

8. Willingness and ability of subject or adult guardian to comply with all study procedures of the study protocol, including attending all clinic visits.

Exclusion Criteria:

1. Body Mass Index (BMI) >30 kg/m2 for adults; >95 percentile BMI-for-age for subjects under 18 years of age.

2. Previous immunotherapy for T1D.

3. Diagnosis of liver disease or hepatic enzymes, as defined by ALT and/or AST =2.5 times the upper limit of normal (ULN).

4. Hematology: white blood cells (WBC) <3 x 109/L; platelets <100 x 109/L; hemoglobin <10.0 g/dL. (Low WBC values may be repeated every 3-7 days, and results to be discussed with the Medical Monitor.)

5. Serum creatinine > 1.5 times ULN.

6. History of malignancy, except for cancers in remission >5 years, or basal cell or in situ squamous cell carcinoma of the skin.

7. Significant cardiovascular disease (including inadequately controlled hypertension, history of myocardial infarction, angina, use of anti-anginal medicines (e.g., nitroglycerin), or abnormal stress test, which, in the opinion of the Principal Investigator (PI), would interfere with participation in the trial.

8. Immunosuppressive therapy (systemic corticosteroids, cyclosporine, azathioprine, or biologics) within 30 days of screening.

9. Current or prior (within the last 30 days) use of metformin, sulfonylureas, glinides, thiazolidinediones, GLP1-RAs, DPP-IV inhibitors, pramlintide, or SGLT-2 inhibitors.

10. Current use of verapamil or a-methyldopa.

11. History of any organ transplant, including islet cell transplant.

12. Active autoimmune or immune deficiency disorder other than T1D or well-controlled autoimmune thyroid disease (e.g., sarcoidosis, rheumatoid arthritis, moderate-to-severe psoriasis, inflammatory bowel disease, and other autoimmune conditions that may require treatment with TNF or other biologics), unless approved by the Medical Monitor.

13. Thyroid-stimulating hormone (TSH) at screening >2.5 mIU/L.

14. History of adrenal insufficiency.

15. Evidence of infection with HBV (as defined by hepatitis B surface antigen (HBsAg)), HCV (anti-HCV antibodies), or HIV.

16. Positive urine pregnancy test: Females of childbearing potential must be excluded if they have a positive urine pregnancy test at screening or randomization or if they are not using medically acceptable methods of birth control. Acceptable methods of birth control include oral or transdermal contraceptives, condom, spermicidal foam, intrauterine device (IUD), progestin implant or injection, abstinence, vaginal ring, or sterilization of partner. The reason for non-childbearing potential, such as bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or 1 year or more postmenopausal; must be specified in the subject's Case Report Form (CRF).

17. Males of reproductive potential who are unwilling to use medically acceptable birth control, unless the female partner is postmenopausal or surgically sterile.

18. Any social condition or medical condition that would, in the opinion of the PI, prevent complete participation in the study or would pose a significant hazard to the subject's participation.

19. Anticipated major surgery during the duration of the trial, which could interfere with participation in the trial.

20. History of drug or alcohol dependence within 12 months of screening.

21. Psychiatric disorder that would prevent subjects from giving informed consent.

22. Participation in other studies involving the administration of an investigational drug or device, including the administration of an experimental agent for T1D, at any time, or use of an experimental device for T1D within 30 days prior to screening, unless approved by the Medical Monitor.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1

Intervention

Biological:
• TOL-3021
TOL-3021 1 mg is a bacterial plasmid expression vector containing the coding sequences for the human proinsulin (hINS) gene.

Other:
• TOL-3021 Placebo
TOL-3021 Placebo

Locations

Country	Name	City	State
United States	University of Miami Diabetes Research Institute	Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Tolerion, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment effect on log-transformed MMTT C-peptide area under the curve (AUC)	The primary outcome is the treatment effect on log-transformed MMTT C-peptide area under the curve (AUC)	52 weeks
Secondary	Rate of clinically important hypoglycemia	glucometer, a single blood glucose level	52 weeks
Secondary	Rate of clinically important hypoglycemia	CGM, =15 consecutive minutes with glucose <54 mg/dL	52 weeks
Secondary	Daily Insulin requirements	Total daily insulin requirements in units per kilogram (kg) body weight	52 weeks
Secondary	Clinical Responder	A clinical responder analysis will be undertaken as a secondary endpoint to further characterize the treatment effect on a clinical level. A positive responder outcome will be defined as no change or increase in C-peptide AUC from baseline vs. Week 52	52 weeks
Secondary	Exogenous insulin-free	Proportion of subjects in each treatment arm who are exogenous insulin-free for at least 3 months with HbA1c levels less than 6.5%	at Week 52
Secondary	Persistent Reduction	Proportion of subjects in each treatment arm who achieve a persistent reduction for at least 3 months in insulin dose to <0.5 units/kg	at Week 52
Secondary	GCM Measurement	Time in range 70-80 mg/dL	at Week 52
Secondary	GCM Measurement	Time >180 mg/dL	at Week 52
Secondary	GCM Measurement	Time >250 mg/dL	at Week 52
Secondary	GCM Measurement	Mean Glucose Coefficient of Variation	at Week 52
Secondary	GCM Measurement	Low Blood Glucose Index (LBGI)	at Week 52
Secondary	GCM Measurement	Glucose below 70 mg/dL Area Over the Curve (AOC70)	at Week 52
Secondary	Other measures of hypoglycemia	Severe hypoglycemia (SH) events (impaired or loss of consciousness requiring assistance of another)	at Week 52
Secondary	Other measures of hypoglycemia	Documented symptomatic hypoglycemia (an event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration <70 mg/dl (3.9 mmol/L))	at Week 52
Secondary	Other measures of hypoglycemia	Total time <70 mg/dL by CGM	at Week 52
Secondary	Other measures of hypoglycemia	Nocturnal hypoglycemia, severe or documented symptomatic episodes (as defined above) occurring after the subject has retired for the primary sleeping period	at Week 52
Secondary	Immunologic	Quantum dot (Q-dot) responses within the qualifying subpopulation to confirm induction of specific autoantigen tolerance	at Week 52
Secondary	Immunologic	Comparison of quantum dot responses within the qualifying subpopulation to clinical outcomes to confirm correlation with specific autoantigen tolerance	at Week 52
Secondary	Immunologic	Determine the effect of treatment on and predictive value of regulatory/protective humoral immune response to proinsulin/insulin	at Week 52
Secondary	Immunologic	Determine the effect of treatment on and predictive value of serum insulin autoantibody affinity for subjects	at Week 52
Secondary	Immunologic	Determine the effect of treatment on and predictive value of insulin autoantibody isotypes (IgA and IgM) and IgG subclasses	at Week 52
Secondary	Immunologic	Determine the effect of treatment on and predictive value of serum insulin, glutamic acid decarboxylase, IA-2, and ZnT8 antibodies by highly sensitive ECL assay	at Week 52
Secondary	Immunologic	Determine the effect of treatment on and predictive value of competition assays of serum insulin and proinsulin IgM and IgG antibodies	at Week 52